Free Trial

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.33 Consensus Price Target from Analysts

Vera Therapeutics logo with Medical background

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus recommendation of "Buy" from the ten brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $63.33.

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald dropped their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright started coverage on Vera Therapeutics in a research report on Monday, May 5th. They issued a "buy" rating and a $75.00 price target on the stock. Wedbush cut their target price on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. JPMorgan Chase & Co. dropped their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. Finally, Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target on the stock.

Get Our Latest Research Report on VERA

Hedge Funds Weigh In On Vera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vestal Point Capital LP increased its stake in shares of Vera Therapeutics by 132.6% during the first quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock worth $60,050,000 after purchasing an additional 1,425,000 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in Vera Therapeutics by 30.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after buying an additional 1,300,410 shares in the last quarter. Lord Abbett & CO. LLC raised its holdings in shares of Vera Therapeutics by 170.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company's stock valued at $48,788,000 after purchasing an additional 727,656 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Vera Therapeutics by 162.2% in the 4th quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock valued at $45,926,000 after purchasing an additional 671,881 shares in the last quarter. Finally, Integral Health Asset Management LLC raised its holdings in shares of Vera Therapeutics by 130.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock valued at $48,634,000 after purchasing an additional 650,000 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Stock Performance

NASDAQ VERA traded down $0.61 during trading on Monday, hitting $19.32. The company's stock had a trading volume of 28,190 shares, compared to its average volume of 787,346. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1.23 billion, a P/E ratio of -7.35 and a beta of 1.28. The firm has a 50 day moving average price of $22.10 and a 200 day moving average price of $32.41. Vera Therapeutics has a 52 week low of $18.53 and a 52 week high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the business posted ($0.56) earnings per share. Equities research analysts forecast that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

About Vera Therapeutics

(Get Free Report

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

See Also

Analyst Recommendations for Vera Therapeutics (NASDAQ:VERA)

Should You Invest $1,000 in Vera Therapeutics Right Now?

Before you consider Vera Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.

While Vera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA’s Secret Picks? 3 Stocks Rising With the AI Giant
NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines